Top member reports
Company Report
Last edited 4 years ago
PerformanceCommunity EngagementCommunity Endorsement
Performance (49m)
7.6% pa
Followed by
19
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#Business Model/Strategy
stale
Added 4 years ago

This is an interesting company.  They are proposing to develop a new biomedical imaging technology that uses magnetic nanoparticles that are specifically targeted to a cancer type.

There are two parts to the strategy.  The first which they have delivered on to some extent is the synthesis of iron oxide particles coated with a stealth polymer coating and conjugated with antibodies that target breast cancer.  The in vitro cell studies for this in breast cancer cell lines looked convincing and the toxicology studies showed low toxicity.  I haven't seen any animal work, but they seem to be looking to do some first in human studies this year. Still a long way to go here but a good start.  They have sold $300k of the nanoparticles to an Israeli company. 

The second aspect is developing the instrumentation that can detect this particles for clinical use.  They have partners for instrument development, but the progress and role of each partner is not clear.  It is also not clear how far off the clinical instruments are from even getting a prototype.  There is a lot of work to do on the instrument side.  In theory the instrumentation they are developing is more sensitive, i.e. can detect smaller tumours, but it is not clear what sort of read out/image would be obtained. 

They can do the first in human studies using MRI systems, but these particles are not ideal contrast agents for use in MRI.  The physics means that particles make images duller (negative contrast) rather than brighter (positive contrast).  Positive contrast is easier to pick up.  In saying that they do have a partnership with Siemens a major MRI system supplier. 

All in all there is potential here, but still lots of work to do to show real clinical efficacy.  We are probably talking at least 10 years for their primary aim of developing clinical magnetic relaxometry scanners.